Harvoni Approval History
- FDA approved: Yes (First approved October 10, 2014)
- Brand name: Harvoni
- Generic name: ledipasvir and sofosbuvir
- Dosage form: Tablets
- Company: Gilead Sciences, Inc.
- Treatment for: Hepatitis C
Harvoni (ledipasvir and sofosbuvir) is a once-daily NS5A inhibitor and nucleotide analog polymerase inhibitor fixed-dose combination for the treatment of chronic hepatitis C virus (HCV) genotype 1, 4, 5 or 6 infection.
Development History and FDA Approval Process for Harvoni
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.